Preventing differentiation syndrome in leukemia with lisaftoclax
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a drug called lisaftoclax to prevent differentiation syndrome, a serious complication that can occur during treatment of acute promyelocytic leukemia (APL). It aims to make treatment safer by reducing the risk of this side effect.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 16 years old
- You must have a confirmed diagnosis of acute promyelocytic leukemia (APL)
- You must be generally active and able to care for yourself (ECOG score 0-2)
- Your liver and kidney function must be within acceptable levels
- You cannot have had another cancer in the past 5 years (except cured skin or early cervical cancer)
- You must not be allergic to the study drugs, and if you are a woman who could become pregnant, you cannot be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests lisaftoclax, alone or with other medicines, in people whose acute leukemia has returned or did not respond to prior treatment. It aims to find out how well the treatment works and how safe it is, especially for patients who may not be able to take standard chemotherapy.
This study tests a new pill (APG-2575, also called Lisaftoclax) combined with a standard injection (azacitidine) for adults with newly diagnosed AML who cannot take strong chemotherapy. The goal is to see if this combination works better than treatment alone.
This study is testing how well a new treatment works for adults who have just been diagnosed with acute lymphoblastic leukemia (ALL), a cancer of the blood and bone marrow. It aims to see if the treatment is safe and effective in helping you reach remission.
This trial tests a new drug called lisaftoclax combined with a standard treatment, azacytidine, for people newly diagnosed with higher-risk myelodysplastic syndrome (MDS). The goal is to see if the combination helps control the disease better than what's currently available.
This trial tests adding venetoclax to standard treatment to prevent a serious side effect called differentiation syndrome in people with newly diagnosed acute promyelocytic leukemia (APL). Patients must be healthy enough to receive intensive chemotherapy.
This trial tests three different chemotherapy regimens for adults 15–65 years old with newly diagnosed acute myeloid leukemia (AML)—a serious blood cancer. The goal is to see which treatment approach works best for patients with intermediate or high-risk disease who are fit enough for intensive chemotherapy.
Hear when a new Acute Promyelocytic Leukemia (APL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.